Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 364 across all filing types
Latest filing 2022-11-14 Investor Presentation
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Investor Presentation Classification · 95% confidence The document is a press release announcing that HLS Therapeutics will present at the Stifel Healthcare Conference, including details about a fireside chat and investor meetings. It does not contain any financial statements, detailed financial data, or regulatory filings. It is an investor presentation announcement rather than the presentation itself or a financial report. The document length is short (1859 characters), and it primarily serves as an announcement of an upcoming event. Therefore, the most appropriate classification is Investor Presentation (IP).
2022-11-14 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Unaudited Condensed Interim Consolidated Financial Statements' for HLS Therapeutics Inc. for the three and nine months ended September 30, 2022. It contains detailed financial statements including statements of financial position, loss, comprehensive loss, changes in shareholders' equity, and cash flows. The notes indicate compliance with International Accounting Standard 34 for Interim Financial Reporting. The document is unaudited and covers a period shorter than a full fiscal year (quarterly and nine months). It includes substantive financial data and analysis, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-11-10 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109F2 Certification of Interim Filings, signed by the CEO, certifying the accuracy and fairness of the interim financial report and interim MD&A for the period ended September 30, 2022. It is primarily an officer certification letter confirming the integrity of the interim filings rather than the filings themselves. The document length is short (3369 characters) and contains no actual financial data or analysis, only certification statements. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as an Interim Report (IR).
2022-11-10 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the CFO regarding the interim financial filings for the period ended September 30, 2022. It references National Instrument 52-109, which pertains to certification of disclosure in annual and interim filings. The document does not contain actual financial data or analysis but is a formal attestation of the accuracy and fairness of the interim filings. The document length is 3372 characters, which is relatively short and consistent with a certification letter rather than a full interim report. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR).
2022-11-10 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis for the Three and Nine Months Ended September 30, 2022' and contains detailed financial discussion, including non-IFRS measures, financial results, and operational overview for the specified interim periods. It references unaudited condensed interim consolidated financial statements and discusses financial performance and business trends for a period shorter than a full fiscal year. The content is consistent with a comprehensive interim or quarterly report rather than a brief announcement or a full annual report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). The document length (15,000 characters) and detailed financial data support this classification with high confidence. 9M 2022
2022-11-10 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of HLS Therapeutics' Q3 Fiscal 2022 financial results, including revenue, EBITDA, net loss, operational highlights, and a renewal of a Normal Course Issuer Bid (NCIB). It contains substantive financial data for the quarter ended September 30, 2022, and includes management commentary on business performance and outlook. The presence of detailed financial tables, discussion of operating expenses, cash flow, and financial position confirms this is a comprehensive quarterly financial report. Additionally, it announces a conference call to discuss these results, which is typical for quarterly earnings releases. The document is not merely an announcement of a report or a certification, but contains actual financial results and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2022
2022-11-10 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.